Reduced CSF p-Tau₁₈₁ to Tau ratio is a biomarker for FTLD-TDP

William T. Hu, MD,
PhD
Kelly Watts, MS
Murray Grossman, MD
Jonathan Glass, MD
James J. Lah
Chadwick Hales, MD,
PhD
Matthew Shelnutt, BS
Vivianna Van Deerlin,
MD, PhD
John Q. Trojanowski,
MD, PhD
Allan I. Levey, MD, PhD

Correspondence to
Dr. Hu:
william.hu@emory.edu

ABSTRACT

Objectives: To validate the ability of candidate CSF biomarkers to distinguish between the 2 main forms of frontotemporal lobar degeneration (FTLD), FTLD with TAR DNA-binding protein 43 (TDP-43) inclusions (FTLD-TDP) and FTLD with Tau inclusions (FTLD-Tau).

Methods: Antemortem CSF samples were collected from 30 patients with FTLD in a single-center validation cohort, and CSF levels of 5 putative FTLD-TDP biomarkers as well as levels of total Tau (t-Tau) and Tau phosphorylated at threonine 181 (p-Tau₁₈₁) were measured using independent assays. Biomarkers most associated with FTLD-TDP were then tested in a separate 2-center validation cohort composed of subjects with FTLD-TDP, FTLD-Tau, Alzheimer disease (AD), and cognitively normal subjects. The sensitivity and specificity of FTLD-TDP biomarkers were determined.

Results: In the first validation cohort, FTLD-TDP cases had decreased levels of p-Tau₁₈₁ and interleukin-23, and increased Fas. Reduced ratio of p-Tau₁₈₁ to t-Tau (p/t-Tau) was the strongest predictor of FTLD-TDP pathology. Analysis in the second validation cohort showed CSF p/t-Tau ratio <0.37 to distinguish FTLD-TDP from FTLD-Tau, AD, and healthy seniors with 82% sensitivity and 82% specificity.

Conclusion: A reduced CSF p/t-Tau ratio represents a reproducible, validated biomarker for FTLD-TDP with performance approaching well-established CSF AD biomarkers. Introducing this biomarker into research and the clinical arena can significantly increase the power of clinical trials targeting abnormal accumulations of TDP-43 or Tau, and select the appropriate patients for target-specific therapies.

Classification of evidence: This study provides Class II evidence that the CSF p/t-Tau ratio distinguishes FTLD-TDP from FTLD-Tau. *Neurology*® 2013;81:1945-1952

GLOSSARY

Aβ42 = β-amyloid 1-42; **AD** = Alzheimer disease; **ALS** = amyotrophic lateral sclerosis; **AUC** = area under the curve; **CI** = confidence interval; **FTD** = frontotemporal degeneration; **FTLD** = frontotemporal lobar degeneration; **FTLD-Tau** = frontotemporal lobar degeneration with Tau inclusions; **FTLD-TDP** = frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) inclusions; **IL** = interleukin; **Penn** = University of Pennsylvania; **PN** = peripheral neuropathy; **PSP** = progressive supranuclear palsy; **p-Tau₁₈₁** = Tau phosphorylated at threonine 181; **ROC** = receiver operating characteristic; **t-Tau** = total Tau.

Frontotemporal lobar degeneration (FTLD) is distinct from Alzheimer disease (AD) and Parkinson disease in that there is poor correlation between the clinical syndromes (such as behavioral variant frontotemporal degeneration [FTD]) and the specific underlying pathology.^{1,2} While some syndromes have better association with FTLD-TDP (FTLD with TAR DNA-binding protein 43 [TDP-43] inclusions) or FTLD-Tau (FTLD with Tau inclusions), it is difficult to use group-level associations to predict each individual's exact pathology. A reliable biomarker that accurately predicts the underlying FTLD pathology at the patient level is desperately needed for successful implementation of substrate-specific therapeutic trials targeting abnormal TDP-43 or Tau accumulations. We previously selected patients with known FTLD-TDP pathology (autopsy, mutations associated with FTLD-TDP, and FTD with amyotrophic lateral sclerosis [ALS] or FTD-ALS) and FTLD-Tau pathology (autopsy, mutations associated with FTLD-Tau,

Supplemental data at
www.neurology.org

From the Department of Neurology (W.T.H., K.W., J.G., J.J.L., C.H., M.S., A.I.L.), Center for Neurodegenerative Diseases Research (W.T.H., K.W., J.G., J.J.L., C.H., A.I.L.), Alzheimer's Disease Research Center (W.T.H., J.G., J.J.L., C.H., A.I.L.), Emory University School of Medicine, Atlanta, GA; and Departments of Neurology (M.G.) and Laboratory Medicine and Pathology (V.V.D., J.Q.T.), University of Pennsylvania, Philadelphia.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Figure 1 Clinicopathologic diagnosis of subjects according to CSF p/t-Tau ratio

The first validation cohort (n = 30) contained 10 subjects (3 with FTLD-TDP) with normal p/t-Tau and 20 subjects (16 with FTLD-TDP) with decreased p/t-Tau, and the second validation cohort (n = 100) contained 61 subjects (6 with FTLD-TDP) with normal p/t-Tau and 39 subjects (27 with FTLD-TDP) with decreased p/t-Tau. FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) inclusions; p/t-Tau = Tau phosphorylated at threonine 181/total Tau ratio.

and FTD with progressive supranuclear palsy [PSP] or FTD-PSP) from the University of Pennsylvania (Penn) to identify novel ante-mortem CSF FTLD biomarkers.³ Using a commercial platform,^{4,5} we found levels of 10 CSF proteins and peptides to differ between FTLD-TDP and FTLD-Tau, with a panel of 5 proteins distinguishing FTLD-TDP cases from FTLD-Tau cases with 84% diagnostic accuracy. To validate these 5 biomarkers, we prospectively recruited FTLD subjects to undergo CSF collection at Emory University and set up independent assays to measure the putative CSF biomarkers as well as levels of total Tau (t-Tau) and Tau phosphorylated at threonine 181 (p-Tau₁₈₁). The most promising biomarker or biomarker panel was then analyzed in a separate validation cohort from Emory and Penn to determine its sensitivity and specificity for FTLD-TDP.

METHODS **Standard protocol approvals, registrations, and patient consents.** Studies conducted at Emory were approved by the Emory Institutional Review Board, and studies conducted at Penn were approved by the Penn Institutional Review Board. We obtained informed consents from each subject or his/her legal representative. W.H. has full access to all the data and final responsibility for the decision to submit for publication.

Subjects. We prospectively recruited volunteers to undergo ante-mortem CSF collection (figure 1). Emory samples included those

prospectively collected from 2010 to 2013, and Penn samples included samples collected from 1997 to 2013. Because the exact FTLD pathology is unknown in most clinically diagnosed patients, we included patients followed to autopsy with neuropathologically confirmed diagnosis of FTLD-TDP or FTLD-Tau (n = 25),⁶ and patients carrying mutations predictive of FTLD-TDP (*C9ORF72*⁷ and *PGRN*;^{8,9} n = 14) or FTLD-Tau (*MAPT*;¹⁰ n = 7). Genetic testing for mutations in *C9ORF72*, *PGRN*, and *MAPT* was performed at Penn for Penn samples, and at Athena Diagnostics (Worcester, MA) or at Penn for Emory samples. We further enriched the cohorts with subjects with FTD-Plus syndromes in which the additional clinical diagnosis accurately predicts the pathology, including FTD-ALS (with ALS characterized by inclusions immunoreactive to TDP-43, n = 16)⁶ and FTD-PSP (with PSP characterized by inclusions immunoreactive to Tau, n = 14).¹¹ Finally, patients with semantic dementia and normal CSF Tau and β -amyloid 1–42 (A β 42) levels (i.e., inconsistent with a diagnosis of AD), a primary progressive aphasia syndrome highly associated with FTLD-TDP after exclusion of AD cases,¹² were also included (n = 7). Consecutive patients were recruited if they fulfilled the inclusion criteria. Each patient underwent detailed neurologic and laboratory examination to ensure the accuracy of clinical diagnosis according to established criteria for AD,¹³ behavioral variant FTD,¹⁴ semantic dementia,¹² FTD-ALS, and FTD-PSP. We did not include subjects with ALS only or PSP only because discovery work using populations preferentially biased toward these 2 groups may reveal CSF changes associated with the particular disease rather than the general FTLD pathologic subtype. In addition, we also recruited subjects with AD, normal cognition with and without peripheral neuropathy (PN) from Emory for this study to determine whether biomarker changes were specific to FTLD-TDP or nonspecifically associated with brain or peripheral nerve disease. *APOE* genotyping was performed at each center.

CSF sampling and analysis. Baseline CSF samples were obtained prospectively before measurement of CSF biomarkers according to protocols similar to the AD Neuroimaging Initiative.^{3,4} Briefly, lumbar puncture was performed with a 20- or 24-gauge spinal needle, and CSF was collected into polypropylene tubes. Aliquots (0.5 mL) were immediately prepared, bar-coded, frozen, and stored at -80°C until analysis. Samples from Penn were shipped overnight on dry ice to Emory and handled in a manner that avoided changes in pH due to exposure of frozen samples to CO_2 and carbonic acid.¹⁵ No complications from lumbar punctures were observed in the current study.

CSF levels of all biomarkers were measured at Emory. CSF levels of A β 42, t-Tau, and p-Tau₁₈₁ were measured with commercially available kits (AlzBio3; Innogenetics, Ghent, Belgium) in a Luminescence 200 platform by a single experienced technician (K.W.) blinded to the FTLD grouping. Specifically, frozen aliquots were allowed to thaw at room temperature for 30 minutes, and each aliquot was then vortexed vigorously for 15 seconds. Once the necessary reagents were loaded into the assay plate, each aliquot was then revortexed for 15 seconds immediately before being loaded into the corresponding wells. In our experience, CSF AD-related peptides become more insoluble with time in vitro, resulting in variable loss of measured levels if the vortexing immediately before well loading is omitted (ranging from 10% in t-Tau and p-Tau₁₈₁ to nearly 50% for A β 42). The ratio of p-Tau₁₈₁ to t-Tau was calculated by dividing p-Tau₁₈₁ by t-Tau.

Levels of other candidate CSF FTLD-TDP biomarkers³ were measured by modifying commercially available immunoassays.

Agouti-related peptides and adrenocorticotrophic hormones were measured in a multiplex assay (75 μ L CSF, overnight primary antibody incubation at 4°C; Millipore, Billerica, MA), while eotaxin-3 (200 μ L CSF, overnight primary antibody incubation at 4°C; Millipore), Fas (100 μ L CSF, 1-hour primary antibody incubation at room temperature; Affymetrix/Procarta, Santa Clara, CA), and interleukin (IL)-23 (200 μ L, 2-hour primary antibody incubation at room temperature; R&D Systems, Minneapolis, MN) were measured in singleplex assays. IL-17 measurements were tried in 5 commercially available kits (Millipore; Life Technologies, Grand Island, NY; Affymetrix/Procarta; R&D Systems; and Affymetrix/eBioscience, San Diego, CA) with no reliably detectable levels. IL-17 in the original biomarker panel was thus replaced by IL-23 because IL-23 is an upstream effector of IL-17 and CSF IL-23 levels were significantly decreased in FTLD-TDP compared with FTLD-Tau in our original study.³

Effects of preanalytical factors on analyte levels. Preanalytical factors may influence CSF analyte levels, including age,¹⁶ sex,¹⁷ duration of freezer storage,⁴ and freeze-thaw cycles. The effects of age, sex, and storage duration were assessed statistically (see below). Freeze-thaw effects were determined empirically by having CSF samples from 5 randomly chosen subjects undergo up to 3 freeze-thaw cycles (figure e-1 on the *Neurology*[®] Web site at www.neurology.org).

Statistical analysis. Statistical analysis was performed in IBM SPSS 20 (Chicago, IL). The χ^2 test and Student *t* test (for 2 subgroups) or analysis of variance (for 3 or more subgroups) were used to detect univariate differences between subgroups. Mann-Whitney *U* tests were used to determine whether levels of agouti-related peptides, adrenocorticotrophic hormones, eotaxin-3, Fas, IL-23, t-Tau, and p-Tau₁₈₁ differed between FTLD-TDP and FTLD-Tau in the first validation cohort. Receiver operating characteristic (ROC) curve analysis was used to determine the area under the curve (AUC) including 95% confidence interval (CI) values, and cutoff points were chosen to achieve sensitivity and specificity greater than 80%.¹⁸ Data from the validation cohort 1 (Emory) were used to calculate the necessary sample size in the 2-center validation cohort 2 (Emory and Penn, with no overlap between the 2 validation cohorts) using G*Power 3.1.5 (Kiel, Germany). With a calculated effect size of 0.93 from validation cohort 1 for p/t-Tau, a sample size of 28 FTLD-TDP and 18 FTLD-Tau has power of 0.90 in detecting a difference in CSF p/t-Tau between the 2 groups at $\alpha = 0.05$. In validation cohort 2, ROC curve analysis was performed with and without the inclusion of AD subjects with increased t-Tau/A β 42 ratio to determine whether the overall predictive accuracy could be improved by incorporating CSF AD biomarkers¹⁸ into the diagnostic algorithm.¹⁹

To determine the effects of preanalytical factors, Mann-Whitney *U* test was used to compare the distribution of p/t-Tau ratio between categorical factors (sex, presence of *APOE* ϵ 4 allele, autopsy status), and linear regression analysis was used to determine the effects of age and collection year.

Levels of evidence. We set out to determine whether there is Class II evidence that candidate CSF biomarkers can reliably distinguish between FTLD-TDP and FTLD-Tau in a 2-center study.

RESULTS We sought to validate putative CSF biomarkers of FTLD subtypes in a single-center validation cohort 1 (*n* = 30) or a 2-center validation cohort 2 (*n* = 100, table). In validation cohort 1,

FTLD-TDP cases had lower p-Tau₁₈₁ levels than FTLD-Tau cases (mean 12.3 vs 19.4 pg/mL, *p* = 0.031, figure 2), and a trend of increased Fas levels and decreased IL-23 levels (*p* = 0.158, *p* = 0.152, figure 2). Levels of the other biomarkers did not differ between FTLD-TDP and FTLD-Tau. Decreased p-Tau₁₈₁ levels alone had moderate performance as a biomarker for FTLD-TDP, with an AUC of 0.750 (95% CI 0.581–0.926) in the ROC curve analysis (figure 3A).

Because previous studies have noted a trend of decreased t-Tau levels in FTLD-Tau,^{3,20} we further analyzed the ratio of p-Tau₁₈₁ to t-Tau (p/t-Tau ratio) to account for possible interindividual differences in the relative Tau phosphorylation at threonine 181. FTLD-TDP cases had significantly lower p/t-Tau ratio than FTLD-Tau cases (mean 0.27 vs 0.47, *p* = 0.005, figure 2), with AUC of 0.804 (95% CI 0.625–0.983) in the ROC curve analysis (figure 3A).

As further validation, we measured CSF levels of Fas, IL-23, p-Tau₁₈₁, and t-Tau in validation cohort 2 including subjects recruited from Emory (no overlap with validation cohort 1 from Emory) and Penn. Validation cohort 2 included patients with FTLD-TDP (*n* = 33), FTLD-Tau (*n* = 20), as well as subjects with AD and elevated CSF ratio of t-Tau to A β 42 (t-Tau/A β 42 >0.39, *n* = 25) and normal cognition (22, including 13 with PN). We included subjects with other central (AD) and peripheral (PN) neurologic disorders to determine whether the observed p/t-Tau phenomenon is specific to FTLD-TDP or merely reflective of brain or peripheral nerve disease. In validation cohort 2, patients with AD were older than patients with FTLD-TDP and FTLD-Tau at the time of symptom onset and time of CSF collection, but all groups were otherwise similar in age at onset, age and disease duration at CSF collection, sex, and education. CSF Fas and IL-23 levels no longer associated with FTLD-TDP in validation cohort 2 (figure e-2). ROC curve analysis showed that p/t-Tau ratio <0.372 differentiated FTLD-TDP cases from all non-FTLD cases with 82% sensitivity and 82% specificity (AUC of 0.838, 95% CI 0.752–0.925, figure 3A; AUC of 0.835 if AD cases were excluded [95% CI 0.739–0.931]), and FTLD-TDP cases from FTLD-Tau with 82% sensitivity and 62% specificity (AUC of 0.731, 95% CI 0.589–0.874).

The observed performance in validation cohort 2 may be attributable to preanalytical factors such as site of collection. We thus determined whether CSF p/t-Tau was influenced by center (Emory vs Penn), age, sex, year of collection, and autopsy status. This analysis revealed that a decreased CSF p/t-Tau ratio in FTLD was not associated with the center of collection (*p* = 0.607), age (*p* = 0.391, figure 3B), sex (*p* = 0.440), or autopsy status (*p* = 0.193). However,

Table Baseline characteristics of the 2 validation cohorts

	Validation cohort 1		Validation cohort 2			
	FTLD-TDP (n = 19)	FTLD-Tau (n = 11)	FTLD-TDP (n = 33)	FTLD-Tau (n = 20)	AD (n = 25)	Healthy control (n = 13)
Male, n (%)	14 (74)	8 (73)	13 (42)	11 (55)	11 (44)	5 (38)
Education, y	15.0 (2.2)	14.3 (2.5)	15.2 (3.0)	14.0 (3.3)	15.9 (2.8)	16.5 (2.7)
FTLD subgroups	4 autopsy; 4 mutation; 7 FTD-ALS; 4 SemD	5 autopsy; 1 mutation; 5 FTD-PSP	11 autopsy; 10 mutation; 9 FTD-ALS; 3 SemD	5 autopsy; 6 mutation; 9 FTD-PSP		
Age at onset, y	65.2 (8.4)	60.8 (10.7)	59.7 (9.5)	58.1 (11.1)	66.2 (7.7)	—
Age at CSF, y	68.9 (8.3)	64.9 (10.1)	62.7 (10.1)	61.8 (11.9)	70.1 ^a (7.8)	66.2 (8.0)
Disease duration, y	3.7 (3.2)	4.0 (2.2)	2.9 (1.9)	3.3 (2.4)	3.1 (2.4)	—
p-Tau ₁₈₁ , pg/mL	12.6 (6.9)	22.0 (13.5)	15.7 (6.9)	20.3 (7.0)	66.2 ^b (45.1)	35.5 (18.3)
t-Tau, pg/mL	65.5 ^c (36.6)	58.3 (29.0)	53.2 (22.1)	52.3 (23.4)	116.4 ^b (72.0)	49.2 (24.4)
p-Tau ₁₈₁ /t-Tau	0.267 ^d (0.110)	0.468 (0.215)	0.311 ^e (0.127)	0.446 (0.137)	0.594 (0.164)	0.646 (0.201)

Abbreviations: AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; FTD = frontotemporal degeneration; FTLD = frontotemporal lobar degeneration; FTLD-TDP = FTLD with TAR DNA-binding protein 43 (TDP-43) inclusions; PSP = progressive supranuclear palsy; p-Tau₁₈₁ = Tau phosphorylated at threonine 181; SemD = semantic dementia with CSF not consistent with AD; t-Tau = total Tau.

Values shown for continuous variables are mean (SD).

^aOlder than FTLD-TDP ($p = 0.038$), Tau ($p = 0.042$).

^bHigher than healthy control ($p < 0.002$), FTLD-TDP ($p < 0.001$), FTLD-Tau ($p < 0.001$), and peripheral neuropathy ($p < 0.06$).

^c $p = 0.017$ compared with FTLD-Tau.

^d $p = 0.002$ compared to FTLD-Tau.

^eLower than healthy control ($p < 0.001$), AD ($p < 0.001$), FTLD-Tau ($p = 0.04$), and peripheral neuropathy ($p = 0.017$).

while CSF p/t-Tau was stable in the FTLD-TDP cases regardless of number of years in -80°C storage ($p = 0.257$ in linear regression model), FTLD-Tau cases from before 2009 had lower CSF p/t-Tau levels than FTLD-Tau cases collected in 2009 or after ($p = 0.017$, figure 3C). This was likely due to higher t-Tau levels in the pre-2009 FTLD-Tau cohort (71 pg/mL vs 50 pg/mL, $p = 0.017$ by Mann-Whitney U test). When only samples collected in 2009 or after were analyzed (figure 3D), CSF p/t-Tau ratio < 0.37 was associated with a high diagnostic accuracy in distinguishing FTLD-TDP from FTLD-Tau cases only (ROC = 0.849, 95% CI 0.725–0.973) or all non-FTLD-TDP cases (ROC = 0.908, 95% CI 0.832–0.983).

Because most autopsy cases had longer freezer storage duration (n = 25, mean 7.7 years) than mutation (n = 21, mean 1.85 years) or clinical (n = 37, mean 0.90 years) cases, the difference in p/t-Tau ratio between FTLD-TDP and FTLD-Tau may be attributable to the inclusion of clinical cases. Therefore, we determined whether the CSF p/t-Tau ratio distinguished between FTLD-TDP and FTLD-Tau within each subgroup as autopsy and mutation confirmation are both criteria for definite FTLD.²¹ Compared with FTLD-Tau cases, FTLD-TDP cases had lower CSF p/t-Tau ratio in both the mutation (n = 0.046) and clinical (n < 0.001) series, but only showed a trend of lower CSF p/t-Tau ratio in the autopsy (n = 0.209) series.

DISCUSSION The design of disease-modifying FTLD clinical trials has been largely hampered by the clinical inability to distinguish patients with FTLD-TDP and FTLD-Tau. In this study, we demonstrated CSF p/t-Tau ratio as a reproducible biomarker for FTLD-TDP in a large number of patients with FTLD recruited from 2 academic centers with known or high-confidence pathology. The performance of reduced CSF p/t-Tau ratio approximates that of the well-established CSF biomarker of t-Tau/Aβ42 for AD,¹⁸ although fluctuations after long-term freezer storage may limit its use in old samples. Assays for the 2 components of this ratio, p-Tau₁₈₁ and t-Tau, are well established in many neurodegenerative disease research centers, and an international standardization effort is already underway given their importance in AD diagnosis and disease-modifying AD trials.²² Our validation of reduced p/t-Tau ratio as an FTLD-TDP biomarker permits the rapid translation of this marker into current and future clinical trials for FTLD-TDP and FTLD-Tau.

The pathophysiologic change that results in a decreased p/t-Tau ratio in FTLD-TDP is unknown at this time. This is likely not due to increased p-Tau₁₈₁ in FTLD-Tau as these cases had lower p-Tau₁₈₁ levels and p/t-Tau ratio than healthy

Figure 2 CSF biomarker levels in FTLD-TDP and FTLD-Tau

Levels of Fas (A), IL-23 (B), p-Tau₁₈₁ (C), and p/t-Tau ratio (D) in validation cohort 1 from Emory between FTLD-TDP and FTLD-Tau. FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) inclusions; IL = interleukin; p/t-Tau = Tau phosphorylated at threonine 181 (p-Tau₁₈₁)/total Tau ratio.

control subjects and AD cases. Alternatively, there may be altered Tau phosphorylation in the brain or CSF of patients with FTLD-TDP that leads to the absence of hyperphosphorylated Tau in patients with FTLD because of the accumulation of pathologic FTLD-TDP. However, there is insufficient evidence to support this possibility, because our immunoassays measured the absolute levels of t-Tau and p-Tau₁₈₁ instead of global phosphorylation within each Tau peptide, and we have not examined phosphorylation status at other Tau residues (e.g., p-Tau₂₃₁). Mass spectrometry methods would be useful to further investigate this issue, but Tau remains poorly detectable in CSF through these methods. Finally, measured levels of p-Tau₁₈₁ and t-Tau include both full-length and cleaved Tau isoforms containing the antigenic sites targeted by the capturing and detecting antibodies, and differential degradation of p-Tau₁₈₁ may occur in different FTLD subtypes.

Another important finding in our study is the differential effects of preanalytical factors on CSF analytes. A major hurdle in the bench-to-bedside translation of promising biomarkers is their technical

and biological validation.^{23,24} Failure to replicate results may be attributable to preanalytical factors (e.g., collection tubes), assay format (immunoassays vs mass spectrometry), biological heterogeneity, and statistical approaches. In the 2 smaller single-center cohorts ($n = 23$ in our earlier work³ and $n = 30$ in validation cohort 1), we found trends of higher Fas in FTLD-TDP. However, this association disappeared in the validation cohort 2 ($n = 53$) at least in part because of the age-associated changes. Age is known to influence levels of CSF biomarkers such as A β 42²⁵ and α -synuclein,²⁶ but its effect is only detectable with a sufficiently powered cohort. Age of the samples also altered CSF p/t-Tau ratio values and IL-23 levels. This effect from sample age reduced the ability of p/t-Tau to distinguish between autopsy-confirmed FTLD-TDP and FTLD-Tau with long freezer storage time, but p/t-Tau still distinguished between the 2 FTLD subtypes with pathogenic mutations fulfilling criteria of definite FTLD, confirming the notion that p/t-Tau reflects the FTLD pathology instead of clinical syndromes.²¹ Sample age is not a new preanalytical factor, as we previously found 4 CSF analytes to undergo age (of the sample) dependent changes in levels.⁴ Whether this is attributable to slow protein turnover, release from interacting proteins, or another mechanism is unclear. Caution is thus warranted when using older stored CSF samples to perform biomarker discovery or validation studies. Because cases in long-term storage are more likely to have autopsy confirmation, future studies must account for storage time and possibly identify alternate gold standards such as pathogenic mutations.

We propose that CSF p/t-Tau ratio is a reproducible CSF biomarker to distinguish between FTLD-TDP and FTLD-Tau. The same ratio can be potentially used to identify cases of ALS without cognitive impairment. In a follow-up study at Penn, one of us (M.G.) determined that ALS cases without dementia showed decreased CSF p/t-Tau compared with control subjects with p-Tau₁₈₁ and t-Tau levels. While characterizing the clinical FTD syndromes remains important in symptomatic management and potentially tracking longitudinal progression,²⁷ the use of a simple, accurate, and minimally invasive biomarker can significantly enhance the design of therapeutic trials focused on abnormal inclusions containing TDP-43, or to exclude subjects with high-likelihood FTLD-TDP from trials that target Tau pathology in FTLD-Tau patients. A previous tauopathy trial limited its enrollment only to patients with PSP because of the poor reliability of using clinical syndromes to predict FTLD-TDP or FTLD-Tau.²⁸ With measures of CSF p/t-Tau ratio readily available in most laboratories involved in AD biomarker research, future clinical trials of drugs that target Tau or TDP can enrich their study population

Figure 3 Diagnostic performance of Tau-related biomarkers in identifying FTLD-TDP

(A) ROC curve analysis of CSF p-Tau₁₈₁ levels (gray dashed line) and CSF p/t-Tau ratio (blue solid line) in validation cohort 1, and the CSF p/t-Tau ratio (black solid line) in validation cohort 2. (B) Analysis of both validation cohorts together showed no significant effect of age on the CSF p/t-Tau ratio. (C) CSF samples collected before 2009 had lower p/t-Tau ratio than CSF samples collected in or after 2009 in FTLD-Tau subjects (red line) but not FTLD-TDP subjects (blue line). (D) When subjects whose CSF was collected before 2009 were excluded, the CSF p/t-Tau ratio remained an accurate biomarker to distinguish FTLD-TDP from FTLD-Tau (black solid line) or all non-TDP cases (black dashed line). FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) inclusions; p/t-Tau = Tau phosphorylated at threonine 181 (p-Tau₁₈₁)/total Tau ratio; ROC = receiver operating characteristic.

with patients with FTD syndromes and normal or low p/t-Tau ratio. Finally, in asymptomatic subjects from families with FTLD-TDP-related mutations, a decrease in CSF p/t-Tau levels may herald early biochemical changes in the brain of these clinically normal subjects, similar to the early decrease in CSF A β 42 levels in asymptomatic subjects with autosomal dominant AD mutations.²⁹ If so, CSF p/t-Tau can be used as a biomarker to identify subjects at very high risk of symptomatic FTLD-TDP for prevention trials similar to those ongoing in familial AD.^{30,31}

AUTHOR CONTRIBUTIONS

Dr. Hu: study concept and design, acquisition of data, analysis and interpretation, statistical analysis, drafting/revision of the manuscript. Ms. Watts, Dr. Grossman, Dr. Glass, Dr. Lah, Dr. Hales, and Mr. Shelnutt: acquisition of data, analysis and interpretation. Dr. Van Deerlin: acquisition of data, critical revision of the manuscript for important intellectual content. Dr. Trojanowski and Dr. Levey: study concept and

design, critical revision of the manuscript for important intellectual content, study supervision.

STUDY FUNDING

Supported by the Viretta Brady Discovery Fund (Emory University), the Alzheimer's Drug Discovery Foundation/the Association for Frontotemporal Degeneration, and the NIH (AG-25688, AG-10124, AG-17586, and NS-44266). Drs. Hu, Grossman, and Trojanowski have a patent pending on reduced p/t-Tau ratio as a biomarker for FTLD-TDP.

DISCLOSURE

W. Hu has received research support from the Association for Frontotemporal Degeneration, the Alzheimer's Drug Discovery Foundation, Bristol-Myers Squibb, and DiaGenic ASA, and has consulted for Sanofi S.A., Anderson Pangia & Associates, and McCurdy & Candler. K. Watts has nothing to disclose. M. Grossman has received research support from the NIH; has served on the scientific advisory boards of Allon Therapeutics, TauRx, and Bristol-Myers Squibb; is on the *Neurology*® editorial board; and has consulted for Forest and Allon. J. Glass has nothing to disclose. J. Lah has received research support from the NIH. C. Hales and M. Shelnutt have nothing to disclose. V. Van Deerlin has received research support from the NIH; has a patent on the Compositions and Methods for the Treatment of Frontotemporal Lobar Degeneration with

TDP-43 Inclusion; and receives publishing royalties from *Molecular Pathology in Clinical Practice* (Leonard DGB, Bagg A, Caliendo AM, Kaul KL, Van Deerlin VM, editors, Springer, 2007). J. Trojanowski has received research support from the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: Modified Avidin-Biotin Technique; US Patent 5,580,898, issued 3 Dec 1996: Method of Stabilizing Microtubules to Treat Alzheimer's Disease; US Patent 5,601,985, issued 11 Feb 1997: Method of Detecting Abnormally Phosphorylated Tau; US Patent 5,733,734, issued 31 Mar 1998: Method of Screening for Alzheimer's Disease or Disease Associated with the Accumulation of Paired Helical Filaments; US Patent 5,792,900, issued 11 Aug 1998: Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants; US Patent 5,849,988, issued 15 Dec 1998: Rat Comprising Straight Filaments in Its Brain; US Patent 6,214,334, issued 10 Apr 2001: Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants to Treat Neurodegenerative Disorders and Brain and Spinal Cord Injuries; US Patent 6,358,681, issued 19 Mar 2002: Diagnostic Methods for Alzheimer's Disease by Detection of Multiple MRNAs; US Patent 6,727,075, issued 27 Mar 2004: Methods and Compositions for Determining Lipid Peroxidation Levels in Oxidant Stress Syndromes and Diseases; US Patent 7,011,827, issued 14 Mar 2006: Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants; Penn 0652, K1828, filed 5 Aug 1998: Method of Identifying, Diagnosing and Treating Alpha-Synuclein Positive Neurodegenerative Disorders; Penn L1986, filed 13 Nov 1998: Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary Frontotemporal Dementia and Parkinsonism Linked to Chromosome-17: Genotype Predicts Phenotype; Penn R3868 (UPN-4439), filed 28 Feb 2005: Microtubule Stabilizing Therapies for Neurodegenerative Disorders; and Penn S-4018, DB & R 46406-217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody; serves on the editorial board of *Alzheimer's & Dementia*; and has received funding for travel and honoraria from Takeda Pharmaceutical Company Ltd. A. Levey has received research support from the Alzheimer's Drug Discovery Foundation and the NIH, and has served on the scientific advisory board of Genomind. Go to Neurology.org for full disclosures.

Received June 13, 2013. Accepted in final form August 26, 2013.

REFERENCES

- Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. *Ann Neurol* 2006;59:952–962.
- Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. *Neurology* 2006;66:41–48.
- Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. *Neurology* 2010;75:2079–2086.
- Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. *Acta Neuropathol* 2010;119:669–678.
- O'Bryant SE. Using blood markers for Alzheimer disease in clinical practice? *Neurology* 2012;79:846–847.
- Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 2006;314:130–133.
- Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 2011;72:257–268.
- Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. *Hum Mol Genet* 2006;15:2988–3001.
- Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 2006;442:916–919.
- Baker M, Kwok JB, Kucera S, et al. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. *Ann Neurol* 1997;42:794–798.
- Ingelsson M, Ramasamy K, Russ C, et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. *Acta Neuropathol* 2007;114:471–479.
- Grossman M. Primary progressive aphasia: clinicopathological correlations. *Nat Rev Neurol* 2010;6:88–97.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939–944.
- Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 1998;51:1546–1554.
- Murphy BM, Swarts S, Mueller BM, van der Geer P, Manning MC, Fitchmun MI. Protein instability following transport or storage on dry ice. *Nat Methods* 2013;10:278–279.
- Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. *Ann Neurol* 2011;69:570–580.
- Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. *J Clin Endocrinol Metab* 2007;92:1129–1136.
- Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol* 2009;65:403–413.
- Acevedo A, Krueger KR, Navarro E, et al. The Spanish translation and adaptation of the Uniform Data Set of the National Institute on Aging Alzheimer's Disease Centers. *Alzheimer Dis Assoc Disord* 2009;23:102–109.
- Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. *Neurology* 2008;70:1827–1835.
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456–2477.
- Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer's Association Quality Control Program. *Alzheimers Dement* 2013;9:251–261.
- Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. *Arch Neurol* 2012;69:1310–1317.
- Hu WT, Holtzman DM, Fagan AM, et al. Plasma multi-analyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology* 2012;79:897–905.
- Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. *Arch Neurol* 2006;63:936–939.
- Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain* 2010;133:713–726.
- Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). *Alzheimers Dement* 2013;9:189–198.

28. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. *Neuropsychiatr Dis Treat* 2012;8:85–93.
29. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012;367:795–804.
30. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. *J Alzheimers Dis* 2011;26 (suppl 3):321–329.
31. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. *Clin Invest* 2012;2:975–984.

The New AAN.com—Neurologist-tested, Member-approved

AAN.com has long been the website of choice for resources at every stage of a neurologist's career. Now, experience the *redesigned* AAN.com. The new site is supported by a simpler, intuitive design, so:

- All of the AAN resources you need are easier to find
- You can access your AAN publications more quickly
- Your CME and maintenance of certification resources are integrated
- Additional resources can help you strengthen your practice
- The robust search engine is more responsive

See for yourself at AAN.com.

Visit the *Neurology*[®] Web Site at www.neurology.org

- Enhanced navigation format
- Increased search capability
- Highlighted articles
- Detailed podcast descriptions
- RSS Feeds of current issue and podcasts
- Personal folders for articles and searches
- Mobile device download link
- AAN Web page links
- Links to Neurology Now[®], Neurology Today[®], and Continuum[®]
- Resident & Fellow subsite

Find *Neurology*[®] on Facebook: <http://tinyurl.com/neurologyfan>

Follow *Neurology*[®] on Twitter: <https://twitter.com/GreenJournal>